格隆汇8月4日丨港通医疗(301515.SZ)公布，截至2025年7月31日，公司通过股票回购专用证券账户以集 中竞价交易方式回购股份，累计回购股份数量为2,858,786股，占公司总股本的2.86%，其中最高成交价 为19.68元/股，最低成交价为16.57元/股，成交总金额为5304.62万元(不含交易费用)。 ...

2024年1至12月份，港通医疗的营业收入构成为：医用洁净装备及系统占比65.42%，医用气体装备及系 统占比29.43%，医疗设备及其他产品销售占比3.01%，运维服务占比1.85%，其他业务占比0.3%。 （文章来源：每日经济新闻） 港通医疗（SZ 301515，收盘价：22.64元）8月4日晚间发布公告称，截至2025年7月31日，公司通过股 票回购专用证券账户以集中竞价交易方式回购股份，累计回购股份数量约为286万股，占公司总股本的 2.86%，其中最高成交价为19.68元/股，最低成交价为16.57元/股，成交总金额约为5305万元。 ...

格隆汇8月4日丨港通医疗(301515.SZ)公布，截至2025年7月31日，公司通过股票回购专用证券账户以集 中竞价交易方式回购股份，累计回购股份数量为2,858,786股，占公司总股本的2.86%，其中最高成交价 为19.68元/股，最低成交价为16.57元/股，成交总金额为5304.62万元(不含交易费用)。 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-046 四川港通医疗设备集团股份有限公司 关于2024年第二次回购公司股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开第四届董事会第十七次会议和第四届监事会第十七次会议，审议通过 《关于 2024 年第二次回购公司股份方案的议案》，公司拟使用不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）的自有资金和专项回购贷款 资金以集中竞价交易的方式回购公司已发行的人民币普通股（A 股）股票，回购 价格不超过人民币 28.49 元/股（含），回购的股份将用于实施员工持股计划或股 权激励。本次回购股份的实施期限为自公司董事会审议通过本次回购股份方案之 日起不超过 12 个月。具体回购股份的数量以回购期满或回购完毕时公司实际回 购的股份数量为准。 公司于 2024 年 11 月 8 日召开 2024 年第一次临时股东会，审议通过《关于 公司 2024 年前三季度利润分配预案的议案》 ...

Summary of Key Points Core Viewpoint - 港通医疗 has shown a slight increase in shareholder numbers, with a modest rise in average shareholding value despite a small decrease in average shareholding quantity [1] Group 1: Shareholder Statistics - As of July 31, 2025, 港通医疗 had 8,816 shareholders, an increase of 100 from the previous period, representing a growth rate of 1.15% [1] - The average number of shares held per shareholder decreased from 11,500 shares to 11,300 shares [1] - The average market value of shares held per shareholder increased from 245,200 yuan to 249,500 yuan [1] Group 2: Stock Performance - During the observed period, 港通医疗's stock price increased by 4.28% [1] - As of the latest report, 港通医疗's stock price was 22.68 yuan, reflecting a decrease of 0.31% [1] - The company's market capitalization stands at 2.268 billion yuan [1] Group 3: Historical Data Comparison - The changes in shareholder numbers and average holdings over the last five reporting dates are as follows: - July 31, 2025: 8,816 shareholders, 11.3 million shares, 249.5 thousand yuan - July 18, 2025: 8,716 shareholders, 11.5 million shares, 245.2 thousand yuan - July 10, 2025: 9,194 shareholders, 9.1 million shares, 231.7 thousand yuan - June 30, 2025: 8,154 shareholders, 11.2 million shares, 249.3 thousand yuan - June 20, 2025: 7,958 shareholders, 12.6 million shares, 233.7 thousand yuan [1]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Kangtong Medical, indicating a mixed outlook with a notable decrease in revenue and profit [1][2]. - On August 1, Kangtong Medical's stock rose by 3.41%, with a trading volume of 83.28 million yuan. The financing buy-in amounted to 7.22 million yuan, while the financing repayment was 8.73 million yuan, resulting in a net financing outflow of 1.50 million yuan [1]. - As of August 1, the total balance of margin trading for Kangtong Medical was 43.36 million yuan, accounting for 2.73% of its market capitalization, which is above the 60th percentile of the past year [1]. Group 2 - The company reported a significant decline in revenue for the first quarter of 2025, with operating income of 24.29 million yuan, a year-on-year decrease of 68.09%, and a net profit attributable to shareholders of 1.58 million yuan, down 85.25% year-on-year [2]. - As of July 18, the number of shareholders for Kangtong Medical was 8,716, a decrease of 5.20% from the previous period, while the average circulating shares per person increased by 5.48% to 7,305 shares [2]. - Since its A-share listing, Kangtong Medical has distributed a total of 48.99 million yuan in dividends [3].

Core Viewpoint - As of August 1, 2025, Kangtong Medical (301515) closed at 22.75 yuan, marking a 3.41% increase, with a trading volume of 37,000 hands and a turnover of 83.2752 million yuan [1] Financial Performance - The company reported a main revenue of 24.2867 million yuan for Q1 2025, a year-on-year decline of 68.09% - The net profit attributable to shareholders was 1.579 million yuan, down 85.25% year-on-year - The net profit after deducting non-recurring gains and losses was 1.4143 million yuan, a decrease of 86.46% year-on-year - The debt ratio stood at 36.26%, with financial expenses of -515,200 yuan and a gross profit margin of 36.15% [5] Market Activity - On August 1, 2025, the net inflow of main funds was 1.4782 million yuan, accounting for 1.78% of the total turnover - Retail investors experienced a net outflow of 2.1398 million yuan, representing 2.57% of the total turnover [1][2] - The financing balance on August 1, 2025, was 43.3562 million yuan, with a net repayment of financing amounting to 1.502 million yuan [3] Industry Comparison - Kangtong Medical's total market value is 2.275 billion yuan, compared to the industry average of 11.474 billion yuan, ranking 117th out of 122 in the medical device industry - The company's net assets are 1.248 billion yuan, significantly lower than the industry average of 3.918 billion yuan, ranking 97th out of 122 - The price-to-earnings ratio (P/E) is 360.21, compared to the industry average of 61.54, ranking 94th out of 122 [5]

来源：金融界 8月1日，港通医疗今日收盘22.75元，上涨3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到429.78倍，创331天以来新低，总市值22.75亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，港通医疗排 名第120位。 股东方面，截至2025年7月18日，港通医疗股东户数8716户，较上次减少478户，户均持股市值35.28万 元，户均持股数量2.76万股。 四川港通医疗设备集团股份有限公司的主营业务是医用气体装备及系统、医用洁净装备及系统的研发、 设计、制造、集成及运维服务。公司的主要产品是医用气体装备及系统、医用洁净装备及系统、医疗设 备及其他产品销售、运维服务。公司先后被评为"国家级专精特新小巨人企业""国家级高新技术企 业""四川省行业小巨人企业""中国气体行业领军企业""全国医用气体优秀工程企业""中国医用气体装备 创新基地""全国医用气体从业人员培训基地"。 最新一期业绩显示，2025年一季报，公司实现营业收入2428.67万元，同比-68.09%；净利润157.90万 元，同比-85.25%，销售毛利率36. ...

Group 1 - The medical waste treatment sector saw an increase of 1.24% as of the market close on August 1, with a total capital inflow of 15.67 million [1] - A total of 25 stocks in the sector experienced gains, while 4 stocks declined [1] - The top-performing stocks included: Saili Medical (6.2%), Zhongshan Public Utilities (4.26%), Xuelang Environment (4.02%), Donghua Technology (4.0%), and Gangtong Medical (3.41%) [1] Group 2 - The stocks with the largest capital inflow were: Saili Medical with 3.49 million, Zhongshan Public Utilities with 6.48 million, and Xuelang Environment with 4.99 million [1] - The stocks that experienced the largest declines included Huakang Clean (−5.97%), Wanbangda (−0.64%), and Zhonggang International (−0.47%) [1] - The overall market sentiment in the medical waste treatment sector appears positive, with significant capital inflow into several key stocks [1]

四川港通医疗设备集团股份有限公司的主营业务是医用气体装备及系统、医用洁净装备及系统的研发、 设计、制造、集成及运维服务。公司的主要产品是医用气体装备及系统、医用洁净装备及系统、医疗设 备及其他产品销售、运维服务。公司先后被评为"国家级专精特新小巨人企业""国家级高新技术企 业""四川省行业小巨人企业""中国气体行业领军企业""全国医用气体优秀工程企业""中国医用气体装备 创新基地""全国医用气体从业人员培训基地"。 最新一期业绩显示，2025年一季报，公司实现营业收入2428.67万元，同比-68.09%；净利润157.90万 元，同比-85.25%，销售毛利率36.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13港通医疗420.52154.351.7822.26亿行业平均 55.2850.194.76115.43亿行业中值38.0638.632.7156.35亿1九安医疗11.0111.130.87185.78亿2英科医疗 13.3414.381.19210.81亿3新华医疗15.4114.281.2698.77亿4振德医疗16.1715.241.0358.70亿5奥美医疗 16.231 ...